Claude Nicaise Form 3 Filing for Chemomab Therapeutics Stock Options

This is a Form 3 filing by Claude Nicaise, a director of Chemomab Therapeutics Ltd. (CMMB), reporting ownership of stock options to purchase American Depositary Shares. The filing discloses six separate stock option grants with varying exercise prices and expiration dates ranging from 2027 to 2036. The options were granted between April 2021 and March 2026, with all but the most recent grant being fully vested and exercisable as of the report date. The filing was made under temporary relief provided by the SEC for foreign private issuers, as it was submitted after March 18, 2026 but before April 20, 2026. Nicaise holds direct ownership of these derivative securities, with exercise prices ranging from $2.14 to $109.04 per share.